EyePoint Reports Second Late-Stage Duravyu Study Failure
EyePoint reported a second late-stage study failure for its proposed Duravyu treatment for wet age-related macular degeneration. Its shares fell sharply on Monday.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.